F. Ruiz

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis

John P. Clancy, Zsuzsa Bebők, F. Ruiz et al. · American Journal of Respiratory and Critical Care Medicine · 2001 · 247 citations

A Clinical Inflammatory Syndrome Attributable to Aerosolized Lipid–DNA Administration in Cystic Fibrosis

F. Ruiz, John P. Clancy, Michael A. Perricone et al. · Human Gene Therapy · 2001 · 183 citations

Inflammatory Lung Disease, Immunodeficiencies, Immunology +17

Adenosine and its nucleotides activate wild-type and R117H CFTR through an A_2Breceptor-coupled pathway

John P. Clancy, F. Ruiz, Eric J. Sorscher · American Journal of Physiology-Cell Physiology · 1999 · 76 citations

Halide Permeability, Molecular Regulation, Gastrointestinal Pharmacology +23

A₂adenosine receptors regulate CFTR through PKA and PLA₂

Bryan Cobb, F. Ruiz, Charles M. King et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2002 · 60 citations